MOUNT PLEASANT, S.C. - January 18, 2023 - (Newswire.com)

Blue Sky Specialty Pharmacy, a leading innovator in the Specialty Pharmacy space, announced recently that they have just received the coveted URAC designation status pursuant to Rare Disease - Center of Excellence, Accreditation.

URAC is the independent leader in promoting health care quality by setting high standards for clinical practice, consumer protections, performance measurement, operations infrastructure, and risk management. By achieving this status, Blue Sky Specialty Pharmacy demonstrates commitment to quality care, enhanced processes, patient safety, and improved outcomes.

"The Rare URAC designation clearly demonstrates our ability to meet rigorous regulatory requirements and National standards. It is the benchmark for the quality of an organization and care they can provide patients with rare diseases. It is an exciting achievement for our team, and we look forward to helping more patients along their healthcare journey," says Blue Sky Founder and CEO Curt Nesbitt. 

"Pharmacies and related pharmaceutical services play a critical role in the health care delivery system now more than ever. Given the complicated nature of chronic disease, pharmacies like Blue Sky Specialty Pharmacy do much more than simply fill a prescription. As trusted experts at the frontline of care delivery, they often provide targeted patient support and education to ensure proper medication management," said URAC President and CEO Shawn Griffin, M.D.

To learn more about Blue Sky Specialty Pharmacy, visit blueskyspecialtypharmacy.com.

About Blue Sky Specialty Pharmacy

With locations in Mount Pleasant, SC, Daphne AL, and Charlotte, NC, Blue Sky Specialty Pharmacy was founded with the vision to re-imagine pharmacy as we know it. Our goal is to create meaningful and enduring impact on our practices and patients and to alleviate the administrative burden and headaches associated with specialty treatments so our practices and providers can focus on treating patients.

About URAC

Founded in 1990 as a non-profit organization, URAC is the independent leader in promoting health care quality and patient safety through renowned accreditation programs. URAC develops it's evidence-based standards in collaboration with a wide array of stakeholders and industry experts. The company's portfolio of accreditation and certification programs span the health care industry, addressing health care management and operations, pharmacies, tele-health, health plans, medical practices and more. URAC accreditation is a symbol of excellence for organizations to showcase their validated commitment to quality and accountability.

Contact Information:
Sara Glime
Marketing Director
[email protected]
8439367076


Press Release Service by Newswire.com

Original Source: Blue Sky Specialty Pharmacy Gaines New URAC Rare Disease Status

DeepView® accuracy increases to 86% in diagnosis of DFU healing potential on day one

DALLAS - January 18, 2023 - (Newswire.com)

Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care, announces the interim results for its Diabetic Foot Ulcer ("DFU") Clinical Study, initiated in June 2022. The DeepView® Wound Imaging System diagnostic accuracy calculated in the interim analysis, being the prediction of a 50% DFU size reduction by week four, has improved five-percentage points to 86% on day one. This increase in diagnostic accuracy will strengthen the Company's planned 2023 FDA submission for its DeepView® DFU indication.

The four-week milestone in DFU reduction in the clinical treatment pathway for a DFU patient is meaningful to determine if alternative treatment is needed. The interim analysis was performed with an initial 100 U.S. adult subjects out of the targeted 200 subjects enrolled and showed: 

• 86% diagnostic accuracy, from the previously reported 81%
• 89% sensitivity 
• 83% specificity

Currently, there are no diagnostic tools available in DFU healing prediction. The standard of care for DFU relies on physicians using a wait-and-see approach of up to 30 days to determine if there is a need for advanced intervention.

The DFU study is currently running at five clinical sites in the U.S.  As the Company's regulatory strategy evolves, it is adding additional clinical sites, three contracted, to ensure study completion in 1H 2023. The Company plans to announce additional EU/UK DFU clinical studies in the near future and will provide updates accordingly. The Company remains on track to complete its FDA 2023 regulatory submission. 

Niko Pagoulatos, Chief Operating Officer of Spectral MD, said: "We are encouraged by the interim observations from the DFU Clinical Study, and we look forward to completing enrollment to finalize DeepView® DFU indication performance analysis and to submit for regulatory approvals. The results from the interim analysis further validate how the DeepView® technology could significantly help transform the lives of people suffering from Diabetic Foot Ulcers." 

Dr. Brock Liden, Podiatry Wound Specialist at Wound and Feet Liden and Principal Investigator in the DFU Clinical Study, commented: "These are extremely encouraging results that show the incredible potential of DeepView® to significantly transform how we treat, manage, and assess Diabetic Foot Ulcers. Diabetic Foot Ulcers are unusually challenging due to the many comorbidities associated with diabetes, which may interrupt the healing process. I look forward to the continued collaboration with Spectral MD as we work to collect meaningful data to further validate this transformative technology."

Burn Indication Update:

The Company has been working on the BARDA funding contract for the Burn indication, and the recent US $ 8.2 million contract expansion with BARDA continues to support interoperability features and commercial readiness for the DeepView® Wound Imaging System. The updates for the current DeepView® Burn AI Training Study are:

• Since year end 31 Dec. 2022, adult enrollment is complete.
• The study population covers demographic and geographic variability.
• The study is currently performed at 11 world-renowned research hospitals, with additional pediatric research sites established.
• Study is expected to be completed 1H 2023.

Spectral MD is in constant communication with BARDA to further develop its infrastructure readiness for a federal-level commercial contract. 

About Spectral MD:                                                                                   

We are a dedicated team of forward-thinkers striving to revolutionize the management of wound care by "Seeing the Unknown" ® with our DeepView^® Wound Imaging System.

www.spectralmd.com

[email protected] 

Contact Information:
Haley Schneider
Marketing Specialist
[email protected]


Press Release Service by Newswire.com

Original Source: Spectral MD Announces Positive Interim Results From DFU Clinical Study & Burn Clinical Study Update

FRISCO, Texas - January 17, 2023 - (Newswire.com)

IDLife, LLC CEO Josh Paine has appointed Robert White as the new Chief Financial Officer, and Justin Sparks will transition to the company's Chief Financial Analyst. 

"A company's ability to grow vertically is determined by its willingness to invest in its foundations and leadership. We are thrilled to welcome Robert White to our IDLife family. His proven leadership, relationships and core values make him the perfect fit for where we are headed as a company. Additionally, allowing Justin Sparks to focus on financial modeling, predictive analytics and machine learning allows IDLife to better serve our growing base of Associates and Customers and give them the information and tools that they need to excel in this rapidly changing marketplace," said Paine. 

As Chief Financial Officer, White will lead the company's financial activities including accounting, controllership, tax, treasury, investor relationships, and more. 

About Robert White

Robert White is a well-appointed Certified Public Accountant with over 30 years of experience. Before joining IDLife, White has held various professional accounting positions and has 10 years of experience in the social selling industry. "I couldn't be more excited to join the team at IDLife and support a legacy of great products and great people," said White. 

Forward Progress

IDLife founder and owner Logan Stout is proud of the decision to bring White to the team and believes this is just another sign of the exciting future ahead. "I'm proud of Josh and the team. It's incredible to have attracted this caliber of individuals working together to advance the company's mission. This addition just further brightens the company's future for growth, impact and momentum," said Stout. 

IDLife continues its massive growth plan in 2023. Paine's vision to create a connected, robust community of people committed to healthy living is moving full steam ahead. The Company is excited to help thousands more people do life better!

Contact Information:
Amanda Green
Director of Marketing
[email protected]
972-987-4430


Press Release Service by Newswire.com

Original Source: IDLife, LLC CEO Josh Paine Continues to Build a Dream Team

An Interview with Business Development Manager Paige Pontrelli

AURORA, Ill. - January 17, 2023 - (Newswire.com)

At Mental Health Technologies (MHT), they bring awareness to mental health concerns daily. However, each year everyone goes from the hustle and bustle of the holidays to feeling weary. That is why every year in January, the nation focuses on mental wellness.

MHT is a cloud-based platform used by medical practices to assess mental health disorders, including substance abuse. MHT identifies areas in which patients are struggling and directs them to the proper behavioral healthcare through a referral process. In a recent interview, one of MHT's leading sales representatives, Paige Pontrelli, answers MHT's frequently received questions:

• What makes MHT stand out from its competitors?

MHT has over 45 different assessments, from depression, anxiety, drug and alcohol abuse, pain, sleep, ADHD, and many more. This gives clinics a wide range of assessments, enabling a range of specialties to screen for any disorder.

Paige says, "MHT has so much to offer any type of medical practice. We can integrate into any electronic medical record, making the assessment process seamless. It adds no additional work to the clinic staff. Assessments are sent to the patient via text or email prior to their appointment. Once completed, the assessments are automatically uploaded into the patient's chart for their provider to review for the appointment."

"We have what's called SmarTest—end-to-end testing for all patients for any disorder. The clinic sets the rules of who to test, as well as when and the assessments to use. SmarTest does the rest. These rules can be based on prior scores, age, gender, diagnosis, insurance information, etc."

• Why should MHT be trusted by medical professionals?

According to Paige, one of MHT's biggest selling points is that MHT is HIPAA compliant and uses Amazon web services for security. It has brought on an expert billing consultant to help clients properly bill for assessments. 

"We also offer a 30-day free trial to all of our new customers," Paige says. "During the trial, we work closely with them to make sure MHT is running smoothly within their practice. We work alongside their billing team to ensure proper and seeing accurate reimbursements."

• How does MHT build and sustain client relationships?

MHT keeps in regular communication with customers through emails, phone calls, Zoom, and face-to-face meetings. 

"We also send regular reports based on their preferred cadence. Each one of our clients receives quarterly reports as well as an annual end-of-year report and meeting," says Paige.

• What assessments are most used by medical practices? 

"As a leading salesforce within MHT," Paige says, "the main assessments clinics use are PHQ-9, depression, GAD-7, anxiety, DAST, drug abuse, AUDIT, alcohol.

"MHT has over 45 different assessments and depending on the type of clinic they are, they may use different assessments. For example, a pain clinic will use depression and anxiety along with a pain survey and opioid risk assessment."

Contact Information:
John Cray
CTO
[email protected]
630.544.8958

Ernie Wallerstein
CEO
[email protected]
6402400323

Bill Leonhard
VP of Sales
[email protected]
6308038582

Paige Pontrelli
Business Development Manager
[email protected]
6305469816


Press Release Service by Newswire.com

Original Source: Mental Health Technologies Celebrates Mental Wellness Month

BROOKLYN, N.Y. - January 17, 2023 - (Newswire.com)

dock., a highly accessible primary care and urgent care provider, announced the opening of its first two locations at 1022 Nostrand Ave. and 850 Flatbush Ave. in Brooklyn, New York. 

The new locations offer same, next-day and virtual appointments for preventative and family care services in addition to illness and injury care, diagnostic imaging, labs and testing.

This transformative model will significantly increase healthcare access for thousands of underserved residents across Brooklyn. 

"Every citizen in Brooklyn deserves equal access to healthcare," said Alex Curran. "For decades, residents have faced limited options for convenient and comprehensive health care services. At dock., we are proud to increase access to primary and urgent care services and contribute to a stronger and healthier city for all."

Ryan Gessin, Managing Director for Newmark, is excited to work on the expansion of a healthcare company that makes care highly accessible in neighborhoods that need it. 

"Unlike the stereotypical urgent care, dock. is a tech-enabled company focusing on primary care and preventive care in addition to providing the standard urgent care services," said Gessin. "The shortage of primary care doctors is well documented. With dock., patients now have immediate access to their doctors with all their care under one umbrella. This allows patients to be proactive about their health while eliminating the typical red tape in the healthcare system."

dock.'s urgent care services are available for people with non-life-threatening conditions who need to see a healthcare provider within 24 hours but do not require an emergency department, such as sprains, cuts, high fevers and minor infections. Its primary care services include diagnosis and treatment for minor illnesses, as well as reproductive care, family medicine, vaccinations and injections, preventative care, medication management and more.

"Our model facilitates the full coordination of holistic healthcare," said Curran. "Our primary care doctors have immediate, on-site access to high-end urgent care equipment including X-Ray, EKG, and ultrasound machines. They also have the capability of running point-of-care testing for same-day results. Our urgent care physicians will have direct contact with the primary care physician, and any questions related to this patient can be answered immediately."

A personal care captain will be assigned to each patient to help navigate every step of their individual healthcare journey. An intuitive patient portal and mobile app will provide on-demand scheduling and provider communication. 

dock. is open seven days per week from 10 a.m. to 6 p.m.

About dock. 

dock. is a highly accessible Primary Care Retail Practice, that includes Urgent Care services and benefits, and offers a modern, luxurious, and upscale experience with Primary Care, in addition to a full-scale Multi-Specialty Practice. Guided primary care is coordinated carefully to meet your immediate needs and long-term health.

dockmedical.com 

Contact Information:
Amy Copeland
Director of Marketing
[email protected]
(920) 851-2088


Press Release Service by Newswire.com

Original Source: dock. Announces Opening of Two Primary Care and Urgent Care Locations in Brooklyn, New York

MIAMI - January 17, 2023 - (Newswire.com)

Building upon the success of New York City, Dr. Edward Alvarez brings his Medical Spa Madison Avenue Face and Body to Brickell Miami. Located at 175 SW 7th Street in Brickell, Madison Avenue Face and Body looks to introduce procedures and techniques not yet available in the Brickell and Downtown Miami area. Acne treatment with Aviclear, the first and original FDA-cleared energy device for the treatment of mild, moderate, and severe acne, as well as non-surgical body contouring with TruBody devices TruSculpt ID and TruSculpt Flex by Cutera, will be the focus of the practice. Other services such as Botox and dermal fillers will also be offered.

"Our goal in coming to Brickell is to bring the level of professionalism, education, expertise, and luxury that has made our practice a desirable destination in New York City for Medical Spa treatments. Our team makes sure the patient feels special and completely taken care of from the moment they walk in the door to the moment they leave," states Dr. Edward Alvarez, owner and CEO. 

Dr. Alvarez, who has been injecting Botox and Juvéderm fillers for over 15 years in New York City and is a key opinion leader and speaker in the field of medical aesthetics, is joined in the practice by Dr. Gustavo Sepulveda, Board Certified in Internal Medicine and a physician at Mount Sinai Medical Center Miami. 

With doctors and staff that are fluent in English, Spanish, and Russian, the practice is well suited to taking care of the diverse population of the Miami and South Florida area. 

Contact Information:
Alina Alvarez
COO
[email protected]
786 522-6565


Press Release Service by Newswire.com

Original Source: Madison Avenue Face and Body NYC Medical Spa Comes to Brickell Miami

CHICAGO - January 17, 2023 - (Newswire.com)

American Society for Transplantation and Cellular Therapy (ASTCT) will present top awards to leaders in the field of transplantation and cellular therapy at the Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® on Saturday, Feb. 18 in Orlando, Florida. 

Fred Appelbaum, MD will receive the 2023 ASTCT Lifetime Achievement Award. Dr. Appelbaum has devoted his career to the development of transformative therapies for leukemia, lymphoma, and other blood cancers. While with the National Cancer Institute (NCI), he was the lead author on the first publication demonstrating the successful use of cryopreserved autologous bone marrow transplantation in patients with malignant lymphomas, a therapy now used to treat more than 10,000 patients annually in the United States, and many more worldwide. During his research career, Dr. Appelbaum helped to refine stem cell transplantation and contributed to the development of novel non-transplant therapies to treat blood cancers. Dr. Appelbaum has hold leadership roles for national clinical research efforts, serving on the Board of Directors of ASH, ASCO, AACR, and ASTCT. Dr. Appelbaum is currently Executive Vice President of the Fred Hutchinson Cancer Center and co-leader of their program in hematologic malignancies.

Since Feb. 25, 2022, Ukrainian medical professionals have provided top quality care in the midst of active war. The 2022 ASTCT Public Service Award will honor the dedication and resilience of the physicians, nurses, pharmacists and advanced practice practitioners of Ukraine who continue to serve their patients with blood disorders. Professor Sergiy Klymenko, MD, PhD and Sybiryna Korenkova, MD will accept this award on behalf of all Ukrainian medical professionals. 

Leslie Kean, MD, PhD will deliver the E. Donnall Thomas Lecture. The lecture is a special honor given to an individual who has contributed meritoriously to the advancement of knowledge in blood and marrow transplantation. In her presentation Targeting GVHD: From the Bench, to the Bedside, to the FDA, Kean will share her laboratory's work over the past two decades to improve the lives of children and adults undergoing hematopoietic cell transplantation by understanding the molecular drivers of alloreactivity, and controlling these pathways towards the ultimate goal of inducing immune tolerance after transplantation.

Additional information about the 2023 award winners is available on the 2023 Tandem Meetings website. Members of the press are invited to attend the meetings in person or virtually. Follow #Tandem23 for the latest updates on the 2023 Tandem Meetings.

###

About American Society for Transplantation and Cellular Therapy (ASTCT)

ASTCT is an international professional membership association of more than 3,600 physicians, investigators, and other health care professionals from more than 45 countries. Our mission is dedicated to improving the application and success of blood and marrow transplantation and related cellular therapies. We strive to be the leading organization promoting research, education, and clinical practice in the field. For more information about ASTCT, visit www.astct.org and follow ASTCT on Twitter @ASTCT.

Contact Jennifer Kasowicz, Director of Marketing, [email protected], 312-673-4970.

Contact Information:
Jennifer Kasowicz
ASTCT Director of Marketing
[email protected]
312-673-4970


Press Release Service by Newswire.com

Original Source: ASTCT to Present Distinguished Honors at the 2023 Tandem Meetings